BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

Scientists at Brazil's National Center for Research in Energy and Materials (CNPEM) have discovered a biocatalyst called ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with ...

Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, ...

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

Running a multi-product facility requires expertise. And, while technology is important, human expertise remains the most ...

Traditional diagnostic methods, such as bacterial culture and PCR-based testing, can take 24–72 hours, delaying critical ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reissued by investment analysts ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target boosted by equities researchers at Piper Sandler ...

The clownfish-anemone living arrangement is one of the most widely recognized examples of symbiosis. Researchers have made a ...